13.0% of participants who got the placebo had adverse reactions during the
study. This was 3 out 23 participants.
None of the participants had serious adverse reactions.
None of the participants stopped taking study treatment due to adverse
reactions.
What adverse reactions happened during this study?
The most common adverse reaction was a migraine.
The table below shows the adverse reactions that happened during the study.
Some participants may have had more than 1 adverse reaction.
Adverse reactions during this study
Benralizumab Placebo
(out of (out of
Adverse reaction 23 participants) 23 participants)
Migraine 4.3% (1) 4.3% (1)
Flushing 4.3% (1) 0.0% (0)
Injection site pain 4.3% (1) 0.0% (0)
Itchiness 0.0% (0) 4.3% (1)
Muscle pain 0.0% (0) 4.3% (1)
10 | Clinical Study Results